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Mononuclear cell gene expression in NSCLC 115Results: One hundred and forty-one patients with advanced NSCLC were enrolled. They
included 109 (77.30%) patients with adenocarcinoma, 12 (8.51%) patients with squamous cell
carcinoma, and 20 (14.18%) patients with other pathological lung cancer types. A PH model
containing two significant survival-associated genes, CPEB4 and IRF4, could help in predicting
the overall survival of patients with advanced stage NSCLC [hazard ratio (HR) Z 0.48,
p < 0.0001). Adding multiple clinical factors further improved the prediction power of prog-
nosis (HR Z 0.33; p < 0.0001).
Conclusion: Molecular signatures in PB can stratify the prognosis in patients with advanced
NSCLC. Further prospective, interventional clinical trials should be performed to test if gene
profiling also predicts resistance to chemotherapy.
Copyright ª 2016, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Lung cancer is the leading cause of cancer deaths world-
wide with non-small cell lung cancer (NSCLC) being the
most common type.1 Clinical trials for new treatment mo-
dalities for NSCLC have increased in recent decades; how-
ever, the outcome remains dismal for patients with
advanced disease. Accurate staging is important for treat-
ment selection and for estimating prognosis. However,
many variables between individuals such as age, perfor-
mance status, smoking, and ethnicity may contribute
significantly to the outcome of patients with NSCLC.2 The
TNM staging system is the standard prognostic assessment
in which tumor size, lymph node involvement, and distant
metastasis are evaluated.3 Lung cancer is a heterogeneous
disease; therefore, personalized treatment has become a
trend for maximizing treatment efficacy and minimizing
adverse effects.4
Gene expression profiling for prognosis prediction or
personalized medicine is emerging and most strategies
utilize tissue section as the specimen.5 Previous studies
identified transcriptional levels of several genes that
were correlated with clinical outcome in lung cancer
patients, based on resected lung tissues. However, this
approach is only feasible in patients with early stage lung
cancer.5e10 Patients with advanced stage disease typi-
cally undergo a biopsy to confirm the diagnosis. A limited
amount of clinical specimen may be inadequate or
inappropriately processed for extensive gene expression
analysis. Suwinski et al11 proposed using specimens from
bronchoscopic examinations. In a small cohort, they
found that ERCC1 and CA9 had an impact on NSCLC
prognosis. In current clinical settings, a peripheral blood
(PB) sample would be more feasible for patients diag-
nosed with advanced stage disease. Cancer cells enter
blood circulation by invading through tumor-associated
blood vessels.12 It is reasonable to propose that gene
expression in circulating tumor cells may predict the
outcome of patients with advanced disease. Only a few
available reports present data on applying PB mono-
nuclear cells (PBMCs) containing circulating tumors cells
(CTC) for gene expression profiling.13e21
Using tumor tissue samples as a source, Chen et al5
defined 16 prognosis-associated mRNA markers a Taiwancohort of non-small cell lung cancer (NSCLC) patients. In
the previous study,5 12 mRNA markers with increased
expression level were poor prognostic factors, while four
other markers with reduced expression were protective
factors. In our study, PB was collected from patients with
advanced NSCLC and processed for the gene expression
analysis of 12 poor prognosis risk markers via real-time
polymerase chain reaction. The four protective markers
with reduced expression were not studied since they may
not be consistently detectable in PB on account of the
potentially low numbers of CTC. There may be a high
probability of identifying tumor cell-derived markers in
PB because these mRNA markers are well documented as
being lung tumor tissue-specific. By combining clinical
risk factors with gene expression signatures, a correla-
tion was established between survival and gene expres-
sion in these patients. The predictive value of PB gene
expression on the survival of patients with advanced
NSCLC was validated.Methods
Patients and blood samples
One hundred and forty-one patients with clinically
confirmed NSCLC were enrolled (June 2006eApril 2013) in
a prospective investigational protocol that was approved
by the Institutional Review Board at Tri-Service General
Hospital (Taipei, Taiwan). The disease stage was classified
in accordance with the TNM system utilized by the AJCC
Cancer Staging Manual,22 7th edition by the American
Joint Committee on Cancer. Forty-two (29.79%) patients
had Stage IIIB disease and 99 (70.21%) patients had Stage
IV disease. The pathological types of cancer were
adenocarcinoma in 109 patients (77.30%), squamous cell
carcinoma in 12 (8.51%) patients, and other pathological
types in 21 (14.18%) patients. Data on the vital status
were available through August 13, 2013.
Before any treatment, patients provided written
informed consent. Samples of PB (6e8 mL) were then
drawn. Blood samples were stored at 4C until the isola-
tion of PBMC fraction within 3 hours. The PBMC fraction
was used for further preparations, as described by Huang
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scription, and real-time PCR analysis. All RNA and cDNA
samples were stored at 80C before analysis.
Cell cultures
A human lung adenocarcinoma cell line, A549, was obtained
from Bioresourse Collection and Research Center (Hsinchu,
Taiwan; catalog number, BCRC60074) and maintained in
Ham’s F-12K medium with 2mM of glutamine adjusted to
contain 1.5 g/L sodium bicarbonate supplemented with 10%
fetal bovine serum. The cells were incubated in 5% carbon
dioxide and humidified at 37C for growth. Cell cultures
were split 10-fold every 3e4 days.
Validation of the reference genes and real-time
PCR sensitivity assay
Human lung adenocarcinoma cell line A549 was spiked into
blood samples from healthy volunteers at concentrations of
0 cells/mL, 50 cells/mL, 100 cells/mL, 300 cells/mL,
1000 cells/mL, and 3000 cells/mL. The samples were pro-
cessed for isolation of the PBMC fraction. Total RNA
extraction, cDNA synthesis, and real-time PCR assay were
performed using the predesigned gene-specific amplifica-
tion primers HK-HPRT1 primer (Advpharma, New Taipei
City, Taiwan) and HK-ACTB primer (Advpharma). The
average of five repeated measurements (cycle number; Cp-
values), which was derived from the graded A549 spike-in
samples, was 28.84  0.57 for HPRT1 and 18.50  0.77 for
ACTB. The Cp-values of HPRT1 [i.e., Cp(HPRT1)] had a
medium-low expression level, which corresponded to the
findings by Dheda et al.24 Because the Cp-values of the
investigated genes in this study had a similar expression
level, all test results confirmed that HPRT1 was a repro-
ducible and proper reference gene for real-time PCR assays
for our study. The expression level of each investigated
gene in a sample or cell was normalized to that of HPRT1
and is presented as the delta-Ct (DCt) value [i.e.,
Ct(HPRT1) e Ct(test)], which is inversely correlated with
the gene expression level.25
For assessing the sensitivity of real-time PCR, all blood
samples (with and without the spike-in) were simulta-
neously processed for the isolation of PBMC fraction and
total RNA extraction. Quantitative real-time PCR of
A549 cell numbers in the spike-in blood sample using ker-
atin 19-primers (KRT19 Primer; Advpharma) was performed.
The HPRT1 mRNA level was used as the reference for
normalization using real-time PCR assay. A reaction mixture
without cDNA was used as the negative control to confirm
PCR assay quality during each analytic batch.
Each reaction mixture contained 1/20 volume of cDNA
derived from 500e20 cells/mL blood as a dilute percentage
for the experiment. Therefore, the cell number equivalents
were 25 cells/assay, 15 cells/assay, 5 cells/assay, 2.5 cells/
assay, 2 cells/assay, 1.5 cells/assay, and 1 cell/assay. To
assess the detection performance, the Cp(KRT19) of each
sample was first normalized with the Cp(HPRT1), and ob-
tained OCp Z Cp(HPRT1) e Cp(KRT19). The relative
change of each spiked sample was then calculated as
OCp ZOCp(Reference) eOCp(spike-in sample).Statistical analysis
The KaplaneMeier (KM) method was used to estimate the
overall survival (i.e., death from all causes). Differences in
survival between risk factors were analyzed with the log-
rank test. The univariate Cox model was used to assess the
association between each gene expression and overall
survival. Furthermore, the multivariate Cox proportional
method was used to evaluate the association between
survival and the independent influence of prognostic fac-
tors, including all gene expressions, sex, smoking status,
and Charlson comorbidity index (CCI).11 The stepwise pro-
cedure was chosen to determine the most significant risk
factors in each model in which the inclusion and exclusion
criteria were set to 0.2. The patient’s risk score was
computed by summing the estimated coefficients times the
corresponding predictor values. Using the median risk score
as the cutoff value, patients were classified into the low-
risk group or high-risk group. A high-risk score meant a
poorer prognosis for patients. The hazard ratio (HR) be-
tween the high-risk and low-risk groups was again obtained
by the univariate Cox model to assess the predicative
power for the model. Furthermore, the likelihood
displacement statistic, Martingale residuals, and the score
residuals were used to inspect the model adequacy.26 In
particular, the influential and poorly fit subjects were
identified by the likelihood displacement statistic and
Martingale residuals. The unusual influential subjects for
each covariate were inspected through the score residuals.
Results
Assessment of the feasibility and sensitivity of the
PBMC-based molecular assay
We used A549 cell-spiked whole blood obtained from
healthy volunteers to mimic blood sample containing CTCs
for the feasibility test. To determine in which subfraction
these spiked A549 tumor cells may be located after the
blood sample preparation, the Ficoll-based method was
applied to separate plasma, mononuclear cells, gran-
ulocytes, and red blood cells. Total RNA extraction of these
subfractions and cDNA synthesis were performed on the
patients’ blood samples. The following PCR tests using A549
cell-specific KRT19 Primer (Advpharma) were performed to
detect the spiked A549 cells since KRT19 is a A549-specific
molecular marker.20,27 The test results showed that the
A549 cell-specific PCR product was mostly observed for the
mononuclear cell fraction, a weak signal for the granuocyte
fraction and no signal for plasma and red blood cells.
Different concentrations of A549 cell-spiked blood samples
were used to evaluate the detection sensitivity of the
molecular assay. Blood samples without the spike-in tumor
cells were the reference.
Assays with the serial spiked A549 cells showed very
good linearity (R2Z 0.9934) between the spike-in A549 cell
numbers and the relative quantitative change measured by
real-time PCR assay. In summary, the spike-in test results
showed that the spiked A549 cells at a concentration of >
5 cells/mL blood could be consistently detected using the
assay method described.
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samples
Twelve tumor tissue-specific prognosis risk genes with
increased expression in NSCLC (i.e., HR > 1), based on
previously published findings,5 were selected as investi-
gating genes at the beginning of this study. High-risk genes
were ERBB3, DUSP6, MMD, CPEB4, RNF4, STAT2, NF1, DLG2,
IRF4, HMMR, HGF, and ZNF264.
Real-time PCR assays for the expression of these 12
genes were performed initially with a small cohort of 10
clinical samples to evaluate PCR specificity and reproduc-
ibility of measurements. After completing this learning set,
eight genesdDUSP6, MMD, CPEB4, RNF4, STAT2, NF1, IRF4,
and ZNF264dcould be reproducibly assayed using the PB
samples and were selected for further investigation in all
patients.Demographics and histopathology as risk factors for
survival
The average age for our cohort was 65.5  12.3 years.
Among them, 63.12% were male, 54.61% were older than
65 years, and 41.84% had never smoked. Characteristics
such as sex, age, smoking status, and pathological type,
were significantly associated with overall survival, based on
the log-rank test (Table 1). In particular, the median sur-
vival time for female patients was 2.28 times longer than
that for male patients. Patients older than 65 years had a
shorter median survival time than younger patients
(9.23 months vs. 22.6 months). Furthermore, patients who
were nonsmokers had stage IIIB cancer or who had adeno-
carcinoma had longer survival times, compared to smokers,
and patients with stage IV and other NSCLC tumor types. In
addition, the CCI was inversely correlated with overall
survival. Patients whose CCI value was 3e5 had a median
survival time longer than 3 years. The median survival time
decreased dramatically to 1.6 years for patients with a CCI
value of 6e8 and less than 1 year for patients with a CCI
value greater than 8.Table 1 Medium survival time for each demographic character
Characteristic Categories Patient
Sex Female 52
Male 89
Age 65 64
>65 77
Smoking status Nonsmoker 59
Smoker 82
Clinical Stage IIIB 42
IV 99
Type Adenocarcinoma 109
Other 20
Squamous cell carcinoma 12
Charlson Comorbidity Index 3e5 23
6e8 43
>8 75Univariate Cox analysis of expressing genes and
survival
Table 2 lists the HR from the univariate Cox regression
analysis of the association between each expressing gene
and survival. Risk genes were associated with a HR more
than 1 for death, whereas protective genes had a HR less
than 1. Among the eight genes, only two genes, CPEB4 and
IRF4, were significantly associated with survival, based on
PB samples; however, the other six genes were significant
prognostic factors, based on lung tumor tissue samples.5
Depending on the HR, for every unit increase in CPEB4
gene expression, the hazard rate increased 31%, whereas
for every unit increase in IRF4 gene expression, the hazard
rate declined 28%.
Multivariate Cox proportional hazards models and
survival
The multivariate Cox proportional hazards (PH) method was
implemented to evaluate the association between eight
genes and three clinical factorsdsex, smoking status, and
CCIdwith overall survival. Gene signatures were included
in the PH models without clinical factors (Model 1) and with
clinical factors (Model II).
The stepwise approach using the multivariate PH model
was computed, and selected the same two significant genes
for Model I and Model II as those obtained from univariate
regression analysis (Table 3). Model I contained two signif-
icant survival-associated genes: CPEB4 and IRF4. Model II
included the same gene signature and two additional clin-
ical factors: sex and CCI. The levels of significance and HR
for CPEB4 and IRF4 remained similar to those in Model I. In
addition to gene expression, men had a higher HR than
women (HRZ 1.91; pZ 0.0023). For every unit increase in
CCI, the HR increased 18%.
Risk scores and overall survival
For genes and clinical factors that were significantly asso-
ciated with overall survival, we used a linear combinationistic.
No. % Median survival, no. of days (range) p
36.88 861 (631e1275) <0.0001
63.12 378 (269e458)
45.39 678 (505e961) 0.0001
54.61 277 (240e400)
41.84 739 (430e1143) 0.0002
58.16 400 (282e490)
29.79 875 (478e1275) 0.0027
70.21 424 (276e517)
77.30 588 (433e739) 0.0014
14.18 292.5 (159e564)
8.51 196 (21e431)
16.31 1401 (564e1988) 0.0001
30.50 588 (431e678)
53.19 307 (240e429)
Table 2 Univarite Cox model for genes.
Gene ID Gene name Hazard ratio
(95% CI)
p
DUSP6 Dual specificity
phosphatase 6
1.05
(0.83e1.32)
0.6822
MMD Monocyte to
macrophage
differentiation-associated
1.10
(0.93e1.31)
0.2536
CPEB4 Cytoplasmic
polyadenylation
element binding
protein 4
1.31
(1.12e1.55)
0.0011
RNF4 Ring finger
protein 4
0.80
(0.59e1.09)
0.1571
STAT2 Signal transducer
and activator of
transcription 2 (113 kDa)
0.90
(0.66e1.22)
0.4924
NF1 Neurofibromin 1 1.39
(0.98e1.97)
0.0657
IRF4 Interferon regulatory
factor 4
0.72
(0.55e0.94)
0.0160
ZNF264 Zinc finger protein 264 0.93
(0.70e1.24)
0.6217
CI Z confidence interval.
118 Y.-Y. Wu et al.of the gene expression values weighted by the regression
coefficients to calculate a risk score for each patient. Pa-
tients with a risk score greater than the median risk score
(as the cutoff) were classified into the high-risk group, and
patients with risk scores less than the cutoff value were
classified into the low-risk group. Figures 1A and 1B display
the KM curves for the stratified risk groups using Models I
and II, respectively. Patients in the high-risk group had a
significant lower median overall survival than patients in
the low-risk group (9.9 months vs. 20.75 months), based on
Model I (i.e., gene signature only). In Model II, which
combines gene signature, sex, and CCI, the median overall
survival of high-risk group was also significantly lower,
compared to patients in the low-risk group (8.68 months vs.
28.31 months). The distinction between the KM curves for
the low and high-risk groups for Model I was not as evident
as in Model II. The HR for Model I and Model II for median
survival were 0.48 and 0.33, respectively. These results
indicated that Model I (i.e., gene signature only) was able
to stratify low risk and high risk; the inclusion of clinical
factors in Model II provided even better stratification.
The model adequacy was assessed by the likelihood
displacement statistic, Martingale residuals, and the score
residuals. After examining the three residuals (data notTable 3 Proportional hazards model for genes only and for gen
Characteristic Categories PH Model
Hazard ratio (95%
Sex Male None
Charlson Comorbidity Index None
Gene expression CPEB4 1.37 (1.15e1.63)
IRF4 0.68 (0.52e0.89)
CI Z confidence interval; PH Z proportional hazards.shown), nine patients (010, 026, 028, 043, 100, 112, 117,
128, and 140; Table 4) were classified as potential outliers
or influential points. To understand the discrepancy of the
nine patients from all other patients, the scatter plot of
IRF4 expression level versus the CCI of all patients, strati-
fied by sex is presented in Figure 2. The potential outliers,
except patient 140, had a relatively higher expression level
of IRF4 at each CCI unit. Patients 043, 112, 128, and 140
were female. Patients 028, 043, 117, and 140 were younger
than 65 years. The survival time of these outliers ranged
17.13e77.7 months and their CCI values ranged 4e13. Pa-
tient 117 had a strong influence on the significance of IRF4
for Model II. In particular, when this patient was censored
from the analysis, IRF4 became insignificant (p Z 0.0768).
On censoring all nine outliers, IRF4 had a weak association
with the survival (p Z 0.4632).
Discussion
A certain proportion of cancer patients do not respond to
treatment and have unexpected disease progression during
treatment. In the current era, molecular markers have
been investigated to predict this poor prognosis in NSCLC.
For patients with advanced stage NSCLC for whom there are
inadequate tissue samples, gene testing or gene expression
profiling may not be feasible. Circulating tumor cells have
been associated with a shorter survival in patients with
advanced lung cancer.17 There is no published data on CTC-
derived gene expression and its correlation with cancer
diagnosis or progression. The approach using PB as assay
material is more feasible for most patients and the meth-
odology of gene expression measurement is clinically
applicable. In this study, we intended to quantify valid
cancer gene transcriptional products derived from PBMC-
fractions from NSCLC patients. We have demonstrated
that this approach could be performed to predict the pa-
tients’ outcomes. We began by conducting a pilot study in a
small cohort and measuring the transcription level of 12
tumor tissue-specific genes, based on previous results re-
ported by Chen et al.5 Only eight genes were repeatedly
detected in the PBMCs samples so these were applied to all
clinical samples in this study. Model I, the PH model with a
two-gene signature (i.e., CPEB4 and IRF4), demonstrated a
significant predictive parameter for survival in our cohort.
Additional clinical variables for PH Model II did not influ-
ence the predictive genes, which showed the validity of the
same two-gene signature.
Our sample size was not sufficient; therefore, we could
not check the validation cohort. We instead checked many
types of residuals such as likelihood displacementes plus risk factors.
I (genes) PH Model II (genes and risk factors)
CI) p Hazard ratio (95% CI) p
None 1.91 (1.26e2.90) 0.0023
None 1.18 (1.08e1.28) 0.0001
0.0004 1.30 (1.09e1.56) 0.0037
0.0046 0.72 (0.55e0.95) 0.0185
Figure 1 The KaplaneMeier (KM) method was used to estimate the overall survival, according to the proportional hazards model. (A)
Model I (i.e., gene signature only). (B) Model II [i.e., gene signature, sex and Charlson comorbidity index (CCI)]. Differences in survival
between risk factorswereanalyzedwith the log-rank test. In theupper right corner of thefigure is informationonthemedian survival time
(inmonths); 95% confidence interval (CI); p-value, based on the log-rank test; and hazard ratio (HR) between low-risk and high-risk group.
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Table 4 Clinical characteristics, CCI, and survival status
of nine potential outliers.
No. Patient
ID
Stage CCI Survival
status
Time
(mo)
Treatment
1 010 IV 9 D 25.27 None
2 026 IV 9 D 17.13 C/T
3 028 IV 10 D 38.70 C/T follow by
afatinib
4 043 IIIB 4 D 56.70 C/T follow by
getitinib
5 100 IV 13 D 21.03 C/T follow by
getitinib
6 112 IV 13 D 38.10 Getitinib follow
by C/T
7 117 IV 8 A 65.07 C/T
8 128 IV 11 D 44.43 C/T follow by
getitinib
9 140 IIIB 4 A 58.43 C/T follow by
getitinib
A Z remained alive until August 13, 2013;
C/T Z chemotherapy; CCI Z Charlson Comorbidity Index;
D Z death.
Figure 2 The scatter plot shows the IRF4 expression level versus
026, 028, 043, 100, 112, 117, 140, and 128dare specifically marke
120 Y.-Y. Wu et al.statistics, Martingale residuals, and score residuals to
assess the model adequacy and influential sample points.
Nine potential outliers for Model II, which were identified
by Martingale residuals, all showed relatively better prog-
nosis with a longer survival time (17.13e77.7 months; Table
4). They all had the adenocarcinoma type of disease, which
was confirmed as a significant survival-associated factor.28
These outliers unexpectedly had a better survival among
the late-stage study population, although not all of them
had other favorable prognostic factors such as female sex,
young age, and lower CCI. However, we found eight of nine
patients could tolerate, and were treated with, more than
two lines of chemotherapy, including targeted therapy. In
addition to certain regulated expression of genes, the
combination of the histologic subtype (i.e., adenocarci-
noma) and targeted therapy may be contributing factors for
a better clinical outcome.
Our results demonstrated that among patients with
advanced disease, the elevated transcription of CPEB4 in PB
was associated with shorter survival. CPEB4 activation
promotes protein translation by inducing cytoplasmic pol-
yadenylation. Some clinical studies report increased CPEB4
transcription in patients with pancreatic and metastatic
prostate cancer.29 In cell-based experiments, CPEB4 was
elevated in pancreatic, lung, and ovarian cell lines
compared to nontransformed control cells.30 Huang et al23
also found elevated CPEB4 in PBMC of colon cancerCCI. Outliers identified by Martingale residualsdpatients 010,
d.
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expression also facilitates transcription factors of the SMAD
family to regulate transforming growth factor-beta, which
activates epithelialemesenchymal transition and promotes
further metastasis.31 Our finding that CPEB4 represents a
negative prognostic risk factor in NSCLC patients is consis-
tent with all of the aforementioned evidence.
IRF4, also known as MUM1, is a transcriptional factor
that participates in the immune regulation of lymphoid,
myeloid, and dendritic-cell differentiation.32e34 Lymphoid
malignancy and multiple myeloma have reportedly
increased IRF4, which promotes downstream nuclear factor
kappa B or MYC.35 IRF4 primarily regulates immune
response against infection and regulates interferon-
inducible genes.36 In this study, we demonstrated that
IRF4 was a protective prognostic factor in NSCLC patients in
both PH models.
Compared to PH Model I, Model II included two addi-
tional risk factors: CCI and sex. To understand the inter-
action of these variables, the scatter plot for IRF4 versus
CCI stratified by sex is displayed in Figure 2. Female pa-
tients seemed to have higher IRF4. As CCI increased, IRF4
declined slightly. The influential male patients seemed to
have slightly higher IRF4. Under the same CCI, patients 043
and 140 seemed to have a lower expression of IRF4 than
other male patients. When deleting these influential pa-
tients, the effect of IRF4 on survival could be replaced by
the CCI and sex. IRF4 behaves as a tumor suppressor in B-
cell malignancy, and we assume that it may also be a pro-
tective factor in lung cancer pathogenesis.37 Spitz et al38
has shown that single-nucleotide polymorphisms of IRF4
may have a role in lung adenocarcinoma patients who had
never smoked.12 Our study results are compatible with Spitz
et al. Since all nine IRF4-dependent cases were adenocar-
cinoma. In a previous study by Chen et al,5 IRF4 was shown
to predict poorer survival of NSCLC patients. By contrast,
our study demonstrated that IRF4 has a protective role.
These contradictory data suggest that IRF4 may reflect
tumor-infiltrating lymphocyte activity in tissue section, but
reflect different lymphocyte population in PB.
There are several limitations of this study. First, it was a
noninterventional cohort study in a single institute.
Candidate gene survey was limited to a small group of the
Taiwanese population. Other ethnicities may have different
genetic influences on lung cancer; lung cancer incidence,
and demographics are significantly different in Asia than in
Western countries.39 Second, patients in our study under-
went treatment as clinically indicated with targeted agents
and chemotherapy with or without radiation therapy.
Because these treatment factors were not controlled, the
final results of survival analysis may have been influenced.
To capture as many patients as possible, we enrolled all
NSCLC patients without previous balancing of tumor type.
Most patients had adenocarcinoma. The potential impact of
tumor type was therefore not adjusted. Moreover, the
types of gene mutations in different pathological types may
have differed. Third, our study started from 2006, 3 years
before tyrosine kinase inhibitor (TKI) was approved (in
2009) to treat patients with advanced adenocarcinoma.40
Epidermal growth factor receptor (EGFR) mutation pre-
dicts a survival benefit in patients with advanced adeno-
carcinoma of the lung who undergo TKI treatment.41 In asubgroup analysis, we also found that our patients with
adenocarcinoma had better prognosis, compared to other
pathological subtypes. However, we did not analyze the
difference between NSCLC with and without mutated
EGFR. Whether this mutation could have an impact on the
prognosis of our patients is unknown and will be the subject
of further study.
In conclusion, we have shown that risk assessment using
a model that includes selected gene expression alone or in
combination with clinical risk factors could predict the
clinical outcome of patients with advanced NSCLC. Most
importantly, we showed that PBMC is a convenient and
adequate resource for gene signature testing that would be
available for all patients. Larger cohorts that include other
ethnic groups and studies controlling for treatment regimen
and pathological subtype are necessary to validate our
current results.Acknowledgments
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